Company Overview
| Stock Name | Frontage |
|---|---|
| Stock Code | 01521 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們為合同研究機構,提供貫穿藥物發現和開發過程的一體化、科學驅動的研究、分析和開發服務,協助製藥公司實現藥物開發目標,於美國和中國均擁有業務。 |
| Listing Date | 2019-05-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港銅鑼灣希慎道33號利園一期19樓1920室 |
| Business Address (Hong Kong) | 香港皇后大道東183號合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | frontagelab.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 3.20 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 1e-05 / shares |
| Offer Period | 2019-05-17 to 2019-05-22 |
| Global Offering Shares | 501,910,000 shares |
| HK Public Offer Shares (Initial) | 50,192,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 451,718,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 2,007,640,910 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 41.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,606,112,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 2.68B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +250% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約11.24百萬美元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 134 |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenue | 48,644 | 70,245 | 83,114 |
| Cost of sales | -29,353 | -39,162 | -49,216 |
| Gross profit | 19,291 | 31,083 | 33,898 |
| Other income and gains, net | 312 | 244 | 467 |
| Selling and distribution expenses | -1,894 | -1,569 | -2,585 |
| Administrative expenses | -6,522 | -8,285 | -10,368 |
| Operating profit | 10,074 | 17,792 | 14,135 |
| Net finance costs | -272 | -315 | -378 |
| Share of associates and JVs | 568 | -1,345 | 336 |
| Profit before tax | 10,370 | 16,132 | 14,093 |
| Income tax expense | -3,134 | -5,967 | -2,852 |
| Profit for the year | 6,646 | 10,165 | 11,241 |
| Profit attributable to owners | 6,646 | 10,165 | 11,241 |
Balance Sheet
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Cash and cash equivalents | 3,254 | 4,339 | 16,306 |
| Trade and bills receivables | 8,344 | 13,161 | 19,456 |
| Inventories | 0 | 0 | 73 |
| Total current assets | 17,538 | 30,333 | 44,188 |
| Total assets | 42,639 | 57,191 | 77,464 |
| Total current liabilities | 15,762 | 19,602 | 29,734 |
| Total liabilities | 23,858 | 26,971 | 33,830 |
| Total equity | 18,781 | 30,220 | 43,634 |
| Equity attributable to owners | 18,781 | 30,220 | 43,634 |
| Interest-bearing borrowings | 7,737 | 10,670 | 8,842 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Net cash from operating activities | 9,345 | 6,759 | 22,658 |
| Net cash from investing activities | -7,392 | -7,038 | -11,435 |
| Net cash from financing activities | -2,114 | 1,068 | 1,329 |
| Depreciation of PP&E | 2,668 | 3,005 | 4,234 |
| Amortisation of intangible assets | 0 | 0 | 75 |
| Purchase of PP&E | -4,019 | -3,215 | -5,220 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 3.35 |
|---|---|
| First Day Open | HK$ 3.68 |
| First Day Change | 4.69% |
| First Day Volume | 280684000.0 |
| First Day Turnover | 1007630000.0 |
| Use of Proceeds | 1、預計于上市后12至18個月內將所分配金額約272百萬港元(或所得款項凈額的約20%)用于以下預期開支:
(1)約81百萬港元的款項將用于改善、升級及擴大我們位于美國的現有設施;
(2)約46百萬港元的款項將用于我們計劃于中國上海張江高科技園租賃的總建筑面積約為40,000至50,000平方呎的新設施的翻新;
(3)約39百萬港元的款項將用于改善本集團于美國及中國運營的系統、流程及應用程式;
(4)約106百萬港元的款項將用于為我們的設施購買新設備及技術,以及于美國及中國聘請更多科學家;
2、約545百萬港元的款項(或所得款項凈額的約40%)于上市后12至18個月內將用于有機地擴大及拓寬我們的能力及服務范圍;
3、約408百萬港元的款項(或所得款項凈額的約30%)將用于通過潛在收購;
4、約136百萬港元的款項(或所得款項凈額的約10%)將用作為營運資金及一般企業用途,包括(尤其是)改善我們業務的常規制度、經營及流程。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (4)
Joint Bookrunners (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Hillhouse Funds | 392,422,400 HKD | — | 24.40% | — | 6 months | 2019-11-30 |
| 2 | Worldwide Healthcare Trust PLC | 117,721,600 HKD | — | 7.30% | — | 6 months | 2019-11-30 |
| 3 | 景林资产管理有限公司 | 156,966,400 HKD | — | 9.80% | — | 6 months | 2019-11-30 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 李志和 | — |
| Company Secretary | 張盈倫 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 香港泰格及杭州泰格為控股股東,緊隨全球發售及資本化發行完成後持股51.45%;李松博士持股9.60%;Hillhouse Capital Advisors, Ltd.持股7.77%;Gaoling Fund, L.P.持股7.20%。 |
|---|




